Peptiva

Research Compound Adipotide

€51,00

€51,00 €60,00

FOR IN VITRO LABORATORY RESEARCH ONLY.
Not intended for personal, clinical, diagnostic or veterinary use, or for administration to humans or animals.

Delivery and payment for your destination

Delivery country

BOX NOW parcel locker: €1.59 · estimated 1–2 business days. DPD to an address: €4.43; delivery estimate at checkout.

Cash on delivery where offered. BOX NOW payment is digital via a link before collection; lockers do not accept cash.

DPD: €12.99 · delivery estimate is shown at checkout.

A DPD cash-on-delivery option is available for this country when offered at checkout.

DPD: €12.99 · delivery estimate is shown at checkout.

A Stripe payment link is sent by email. Payment is confirmed before dispatch.

For other destinations, first request confirmation of shipping and product availability. Send enquiry

Information preview. Select your delivery address at checkout.

Full shipping terms

Free DPD shipping from €250 in product value where offered. Final costs and any additional fees are shown before order confirmation. Delivery time starts at carrier handover and depends on product availability.

Full shipping terms →

MAIN RESEARCH AREAS Research profile

Adipose tissue targeting (vascular) Primary

In vitro adipocyte apoptosis Very common

Adipose tissue angiogenesis Common

Lipid metabolism Secondary

Editorial map of the main themes found in the scientific literature. Bar length is not a statistical score, efficacy rating, or indication for human use.

Product information in one place

Specifications and available formats

Strength	5 mg
Format	Lyophilised vial · Research dispenser

This is an overview of options. Select your required variant and its price above.

Description and research information

Research Compound Adipotide is a laboratory material for analytical and in vitro work.

What is Adipotide?

Adipotide (also known as FTPP, prohibitin-targeting peptide 1) is a synthetic peptidomimetic composed of two functional parts: a cyclic CKGGRAKDC motif that binds prohibitin on the endothelium of adipose tissue blood vessels, and the pro-apoptotic sequence D(KLAKLAK)2, which disrupts mitochondrial membranes.

Research background

The molecule was developed by the group of Renata Pasqualini and Wadih Arap at MD Anderson Cancer Center, using phage display to identify peptides that selectively target the blood vessels of specific tissues. Results in mice were published in 2004 and in primates in 2011.

Mechanism and scientific context

The concept is based on vascular targeting: rather than acting on adipose cells directly, the peptide binds to the endothelium that supplies them and induces apoptosis of those cells. The primate study also described effects on renal function, an important part of the molecule's safety profile.

Main research areas

vascular targeting with peptides (phage display)
prohibitin as a vascular marker
apoptotic signalling
adipose tissue vasculature

Level of evidence

Exclusively preclinical. Effects on the kidneys were also described in animal models. Quality human data are not available.

Research use only: for laboratory, analytical and in vitro research only; not for use in humans or animals. Guidance on batch documentation is available in our COA guide.

Storage and handling

Follow the label and documentation for the specific batch. Conditions depend on the material and format; do not assume one storage regime for all products. Request missing information before ordering.

Documentation and lot

Request available records for the exact product, variant and lot. A product name alone does not link a report to the supplied batch.

Request documentation

Quality and documentation →